LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells
This study identifies that serum levels of LPG 18:0 are generally elevated in asthmatics and serve as a biomarker for asthma. LPG 18:0 impairs Treg function <i>via</i> the NAD<sup>+</sup>/SIRT1/FOXP3 pathway. Our research reveals the potential of LPG 18:0 as a biomarker for asthma, elucidating its role in asthma diagnosis and treatment.
Authors
- Lixiang Xue (ORCID: https://orcid.org/0000-0003-1507-7193)
- Yongchang Sun (ORCID: https://orcid.org/0000-0001-9547-9381)
- Zemin Li (ORCID: https://orcid.org/0000-0002-7878-6870)
- Yahong Chen (ORCID: https://orcid.org/0000-0003-3258-8032)
- Ying Shang
- Abudureyimujiang Aili (ORCID: https://orcid.org/0000-0002-6893-5561)
- Yuqing Wang (ORCID: https://orcid.org/0000-0002-4153-3984)
- Rong Jin (ORCID: https://orcid.org/0000-0002-5666-9497)
- Lijiao Zhang (ORCID: https://orcid.org/0000-0002-7803-1056)
- Huan Liu (ORCID: https://orcid.org/0000-0002-0368-2196)
- Chun Chang
- Xu Zhang (ORCID: https://orcid.org/0000-0002-7909-9378)
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1183/13993003.01752-2023
- Citations
- 12
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.92
Funders
- National Natural Science Foundation of China
- Peking University
- Peking University Third Hospital
- Beijing Municipal Natural Science Foundation
- National Key Research and Development Program of China